VivoSeq
Infectious Disease

Human Immunodeficiency Virus (HIV)

8

Pipeline Programs↗

4

Active Trials↗

4

Companies Involved↗

Human Immunodeficiency Virus (HIV) is an early-stage landscape with 8 programs across 4 companies. The most active players are Sanofi, Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Gilead. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

15/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 1C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 2Gilead logo

Gilead

1 program

Phase 3Merck & Co. logo

Merck & Co.

7 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Recruiting3 · 75%
Not yet recruiting1 · 25%

Clinical Trials

Trial Activity

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women
Recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT07071623·4,580 enrolled
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis
Recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT07044297·4,390 enrolled
A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Participants With HIV-1, Who Are 4 Weeks to Less Than 12 Years of Age and Weigh Less Than 45 kg
Recruiting·Merck & Co. logoMerck & Co.·Phase 2·NCT04375800·84 enrolled
An Open-label, Phase 1 Study to Characterize the Effects of Rifampin on the Pharmacokinetics of MK-8527 in Adult Participants With Latent Tuberculosis Infection
Not yet recruiting·Merck & Co. logoMerck & Co.·Phase 1·NCT07600775·14 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)